HHS Does Not Want Judge to Revisit Lawsuit - Even Though the Ruling Was Against Them

The Obama government and the pharmaceutical drug sector are still battling in court about HHS' jurisdiction to compel drugmakers to provide 340B rebates on orphan pharmaceuticals in some cases.

In the most recent battery, HHS is urging a federal judge to decline to revisit his May judgment that the government exceeded its rulemaking authority. HHS asserts that the ruling-- despite the fact that the administration technically lost-- allows administrators to reissue the same policy in a different form. The pharmaceutical manufacturers are requesting the court to clarify that he genuinely meant to prevent the policy.

A stipulation of the Patient Protection and Affordable Care Act left out orphan drugs from the 340B drug-discount program. HHS, nevertheless, has interpreted this omission to apply just when the costly drugs are used to cure the rare conditions in which they were actually created and certified to target.

The Pharmaceutical Research and Manufacturers of America last year filed a legal action arguing that HHS exceeded its rulemaking power by limiting the exclusion. The court of law conceded. But the Health Resources and Service Administration, the HHS agency that oversees the 340B program, later stated it would certainly maintain its interpretation and continue requiring the rebates.

HHS is now crafting the argument in which it can put out an interpretative policy or guidance that establishes the very same guidelines as the legislative rule that the judge struck down, according to court documents filed July 14 in U.S. District Court for the District of Columbia.

"The agency's position on this issue has been correct all along," said a spokesman for the Safety Net Hospitals for Pharmaceutical Access, a trade group for hospitals participating in the 340B program. "We agree that HHS can legally move forward without additional action by this court.".

The lawsuit is one of just one component of an evolving and controversial battle over how the 340B program is utilized. Quick expansion under the Affordable Care Act has actually been an issue for drug manufacturers that are obliged to provide rebates up to FIFTY % on certain outpatient drugs. Some legislators, meanwhile, have stated that some hospitals are inappropriately making use of profits and savings from the program.

Even as both sides wait for future action from the court associated with the law suit, additional concerns still remain about whether or not the suit will further delay the release of proposed policies that were actually anticipated in June. The so-called mega-reg will most likely clarify other elements of the 340B program. David Ivill, a partner with law firm McDermott Will & Emery, stated he expects that the statutes will not be published before the end of the year.

Read more about this 340B story